I’m excited to announce that I’ll be at the #OncologySymposia in Conjunction With the 2024 ASCO Annual Meeting with @ClinicalCareOptions!

Join me for a #CME -certified webinar, where we’ll discuss the latest data on managing anemia in patients with low-risk MDS.

We are hiring a Staff Scientist to support basic and translational studies as part of the Dana-Farber Telomere Biology Disorder (TBD) Multidisciplinary Program. Chris Reilly Team Telomere
careers.dana-farber.org/job/scientist-…

NEW: results from the phase 3 ASAP trial comparing remission induction versus immediate allogeneic transplantation for patients with relapsed or poor responsive acute myeloid leukaemia did not show non-inferiority #leusm #openaccess thelancet.com/journals/lanha…

I have the pleasure and privilege to dive into #BPDCN under the amazing mentorship of the one and only Andy Lane Dana-Farber News. 🌞=>TET2=>Skin involvement| RAS=> Systemic involvement | Overt BM (>5%)=>⬇️OS.

Excellent review by H. Moses Murdock et al on novel strategies in conditioning/maintenance around allo-HCT in AML! #leusm

frontiersin.org/journals/immun…

Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial - thelancet.com/journals/lanha… #leusm #AML

“Multilineage” vs “lymphoid-only” BCR::ABL1 involvement and distinct cooperating events determine gene expression in BCR::ABL1-positive ALL. ow.ly/3fLu50R8JAT #lymphoidneoplasia #clinicaltrialsandobservations

Why do Latino children have the highest risk for childhood leukemia in the US? We identify one cause for this in a paper out in Cell Genomics today, led by Adam de Smith, Lara Wahlster, Soyoung Elizabeth Jeon, Fulong Yu, Charleston Chiang, & colleagues:
cell.com/cell-genomics/…

What are the outcomes of patients with #BPDCN and AML treated with tagraxofusp combined with azacitidine & venetoclax?

Andy Lane (@DanaFarber) discusses the findings in a recent interview:

👉 ow.ly/RiGF50QStgy

#RareDisease #HemOnc #Hematology #ESHAL2024 ESH (Haematology)

Check out our new episode on career development as a clinician investigator with Dr. Ayalew Tefferi! We discuss a range topics pertinent to trainees and junior faculty. You won't want to miss it!

tinyurl.com/tdc5524f

Clip on writing and communicating clearly👇

We recently spoke with Andy Lane (@DanaFarber) at #ESHAL2024 to hear an update on the current treatment landscape for #BPDCN .

Click here to visit our site and watch the interview:

👉 ow.ly/2yka50QNJUh

#RareDisease #HemOnc #Hematology ESH (Haematology)

Important alert to all transplanters! Every #TransplantAllogeneic Doc who sees #MDSsm patients should read this paper by ⁦Coleman Lindsley⁩ !! Please do NOT decline to transplant otherwise eligible TP53-mut higher risk #MDSsm Pts who have donors ascopubs.org/doi/10.1200/JC…

Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. pubmed.ncbi.nlm.nih.gov/38450850/ Five tables, 7 figures and 13 years of work summarized! #CMML #ASXL1 Mayo Clinic Comprehensive Cancer Center The Leukemia & Lymphoma Society AA&MDSIF

Sharing our latest work characterizing CHIP as a risk factor for acute kidney injury (AKI) using human cohort data and mouse models.

Published today in Nature Medicine:
nature.com/articles/s4159…

Maintenance treatment was safe, with low rates of infections and chronic GVHD, and minimal impact on T-cell immune reconstitution. ow.ly/NAUY50QHhfz #clinicaltrialsandobservations #transplantation

Just out in Journal of Clinical Oncology the VALDAC study of LDAC+Ven for MRD relapse or oligoblastic relapse in AML

MRD group: 46% MRD negativity
oligoblastic group: 73% CR/CRh/CRi

2 year OS 67% in MRD group, 53% in oligoblastic group

ascopubs.org/doi/10.1200/JC… Haematology Peter MacCallum CC & Royal Melbourne Peter Mac Research #leusm